GAPAID

Genes And Proteins for AutoImmunity Diagnostics

Coordinatore	TOSCANA BIOMARKERS S.R.L    more  Organization address address: VIA FIORENTINA 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Maria Claudia Cognome: Alcaro Email: send email Telefono: 390577000000
Nazionalità Coordinatore	Italy [IT]
Totale costo	1˙715˙535 €
EC contributo	1˙210˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2012
Funding Scheme	BSG-SME
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-09-01   -   2014-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TOSCANA BIOMARKERS S.R.L  Organization address address: VIA FIORENTINA 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Maria Claudia Cognome: Alcaro Email: send email Telefono: 390577000000	IT (SIENA)	coordinator	181˙015.82
2	PROGENIKA BIOPHARMA SA  Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" city: DERIO - VIZCAYA postcode: 48160 contact info Titolo: Dr. Nome: Sergio Cognome: Escorza Email: send email Telefono: 340944000000	ES (DERIO - VIZCAYA)	participant	581˙507.61
3	Pharma Quality Europe S.R.L.  Organization address address: Via Brunetto Degli Innocenti 2 city: Figline Valdarno postcode: 50063 contact info Titolo: Dr. Nome: Mariola Cognome: Mier Email: send email Telefono: +39 345 624 16 32 Fax: +39 055 952310	IT (Figline Valdarno)	participant	209˙047.25
4	DIAGNOSTICUM GYARTO ES FORGALMAZO ZARTKORUEN MUKODO RESZVENYTARSASAG  Organization address address: ATTILA U 126 city: BUDAPEST postcode: 1047 contact info Titolo: Dr. Nome: Ferenc Cognome: Péterfy Email: send email Telefono: +36 1 3790092	HU (BUDAPEST)	participant	194˙371.32
5	OMNILAB IBERIA SL  Organization address address: CALLE RIOS ROSAS 11 ESCALERA A 11 city: MADRID postcode: 28003 contact info Titolo: Mr. Nome: Alfredo Cognome: Benés Email: send email Telefono: 34637888606	ES (MADRID)	participant	30˙586.00
6	UNIVERSITA DI PISA  Organization address address: Lungarno Pacinotti 43/44 city: PISA postcode: 56126 contact info Titolo: Prof. Nome: Paola Cognome: Migliorini Email: send email Telefono: +39 50 558628	IT (PISA)	participant	13˙472.00
7	EOTVOS LORAND TUDOMANYEGYETEM  Organization address address: EGYETEM TER 1-3 city: BUDAPEST postcode: 1053 contact info Titolo: Dr. Nome: József Cognome: Prechl Email: send email Telefono: +36 1 3812175	HU (BUDAPEST)	participant	0.00
8	PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS  Organization address address: VASVARI PAL UTCA 4 city: PECS postcode: 7622 contact info Nome: Eva Cognome: Somosi Email: send email Telefono: +36 72 5334985 Fax: +36 72 533193	HU (PECS)	participant	0.00
9	UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA  Organization address address: BARRIO SARRIENA S N city: LEIOA postcode: 48940 contact info Nome: Charo Cognome: Sánchez Email: send email Telefono: 34946012142 Fax: 34946013550	ES (LEIOA)	participant	0.00
10	UNIVERSITA DEGLI STUDI DI FIRENZE  Organization address address: Piazza San Marco 4 city: Florence postcode: 50121 contact info Titolo: Prof. Nome: Paolo Cognome: Rovero Email: send email Telefono: 390555000000	IT (Florence)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Rheumatoid arthritis (RA) and sistemic lupus erythematosus (SLE) are two autoimmune diseases that respectively affect an estimated population of 1.537.000 and 1.272.000 of patients in Europe. Such diseases show a long prodrome during which there are no clinical symptoms. In some cases, therapeutic treatments have been developed to improve patients quality of life. Therefore, reliable diagnostic/prognostic tools are necessary not only for an early diagnosis and for monitoring disease activity, but also for setting up personalized therapeutic treatments. The clinical diagnosis of RA and SLE is assisted by the use of in vitro diagnostic tests aimed at the evaluation of the presence/level of few autoantibodies circulating in serum. Yet, this diagnostic approach is unsatisfactory because it can assist the diagnosis only after the first disease onset, it is not useful to evaluate the disease susceptibility for an early prevention, and it does not provide information to follow the disease progression for the set up of personalized therapeutic treatments. To solve these drawbacks, the GAPAID project is aimed at supplying the SME participants of the scientific and technological activities necessary to develop a novel diagnostic / prognostic platform for patients affected by RA and SLE. To this aim the scientific activities will be focused on the discovery of the diagnostic and prognostic value of the genetic and serological profiles associated to RA and SLE. The technological activities will contribute to develop multiplex arrays for the contemporary detection of more analytes and to set up a software for the RA and SLE diagnosis / prognosis by matching the clinical, genetic, and serological data. The exploitation of the scientific and technological results will allow the SME participants to the GAPAID proposal to develop and to further commercialize both for RA and SLE an in vitro diagnostic product composed by a genetic array, a serological array, and a software.'